Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma: A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)

BACKGROUND: Outcome of low-grade glioma (LGG, WHO grade II) is highly variable reflecting molecular heterogeneity of the disease. We compared two different single modality treatment strategies: standard radiotherapy (RT) versus primary temozolomide (TMZ) chemotherapy with the aim of tailoring treatm...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Lancet Oncol
Main Authors: Baumert, Brigitta G., Hegi, Monika E., van den Bent, Martin J., von Deimling, Andreas, Gorlia, Thierry, Hoang-Xuan, Khê, Brandes, Alba A., Kantor, Guy, Taphoorn, Martin J.B., Hassel, Mohamed Ben, Hartmann, Christian, Ryan, Gail, Capper, David, Kros, Johan M., Kurscheid, Sebastian, Wick, Wolfgang, Enting, Roelien, Reni, Michele, Thiessen, Brian, Dhermain, Frederic, Bromberg, Jacoline E., Feuvret, Loic, Reijneveld, Jaap C., Chinot, Olivier, Gijtenbeek, Johanna M. M., Rossiter, John P., Dif, Nicolas, Balana, Carmen, Bravo-Marques, Jose, Clement, Paul M., Marosi, Christine, Tzuk-Shina, Tzahala, Nordal, Robert A., Rees, Jeremy, Lacombe, Denis, Mason, Warren P., Stupp, Roger
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5124485/
https://ncbi.nlm.nih.gov/pubmed/27686946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30313-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares